Alex Sapir - 02 Feb 2026 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Reporting relationship: President & Chief Executive Officer, Director
Issuer ticker: FULC
Reported as of: 02 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:10:02 UTC
Prior SEC filing: 28 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Greg Tourangeau as attorney-in-fact for Alex Sapir

Key filing fact

Alex Sapir filed Form 4 for Fulcrum Therapeutics, Inc. (FULC) on 04 Feb 2026.

Key facts

This page summarizes Alex Sapir's Form 4 filing for Fulcrum Therapeutics, Inc. (FULC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Feb 2026, 16:10.

Change

Previous filing in this sequence was filed on 28 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001709415 Primary reporting owner

Sapir Alex

Relationship: President & Chief Executive Officer, Director
Address: C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE
Signature: /s/ Greg Tourangeau as attorney-in-fact for Alex Sapir
Signature date: 04 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FULC transaction Derivative

Stock option - Right to Buy

Award

Transaction value: $0
Shares: +650,000
Change %
Price: $0.000000
Shares after: 650,000
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 650,000
Exercise price: $10.72
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.

SEC remarks

President & Chief Executive Officer